ClinicalTrials.gg
RecruitingNCT07480785Updated Mar 18, 2026

TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients

An interventional study of transcutaneous electrical acupoint stimulation and Sham transcutaneous electrical acupoint stimulation in Uterine Fibroids (Leiomyoma), Ovarian Tumors and Gallstones, sponsored by Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Zhejiang University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
780
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Leiomyoma with a site in China — 20 open to participants now, 23 under way, 2 of them phase 3. Leiomyoma · China.

Planned enrollment
5th of 29
780 · median 120
Started
2026
with 4 others
No phase
15 of 40
9 open now
Primary completion
2027-10
later than 20 of 22 live
Registered
35th of 40
by date

Among the 40 studies in Leiomyoma with a site in China, this one is the 5th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 with no phase, reaches primary completion later than 20 of the 22 other live ones, and was the 35th registered.

Leiomyoma

439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

20 of the 40 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Leiomyoma with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effects of transcutaneous electrical acupoint stimulation (TEAS) combined with triple antiemetics for postoperative nausea and vomiting (PONV) in high-risk patients.

The primary question it seeks to answer is:

Does TEAS combined with triple antiemetics further reduce the incidence of PONV in high-risk subjects? Researchers will compare active TEAS with sham stimulation to determine whether the addition of TEAS to dexamethasone, palonosetron, and droperidol lowers the PONV rate beyond that achieved by the triple-drug prophylaxis alone.

Read the detailed description

780 female patients, aged between 18 to 65 y, who are scheduled for elective laparoscopic surgery requiring general anesthesia, will be randomly allocated to acustimulation group (Group TEAS), or the control group.

In Group TEAS, a surface electrode will be applied to the P6 and L14 acupoint 30 min before induction. An operator will set electric stimulating current at 1mA with frequency at 2 Hz, and gradually increased the current intensity to a little below discomfort threshold. The stimulation will be maintained until the patient is discharged from the operation. In the control group the same protocol was applied for percutaneous acupoint electrical stimulation, initiated before anesthesia induction with the minimum perceptible current (MPC) and terminated after 1 minute.

A standardized anesthetic protocol will be followed. In all groups, dexamethasone 5mg and palonosetron 0.25mg i.v. will be given after induction, and droperidol 1.25 mg i.v. will be given during the abdominal closure. After surgery, metoclopramide 10mg i.v. will be administered as a rescue therapy to any patient who experiences an episode of moderate or severe nausea, an episode of vomiting, and requests rescue medication.

The patients shall be unaware of the group assignments. An anesthesiologist, who are trained for the study and blinded to the randomization, will collect the data.

03

Conditions studied

  • Uterine Fibroids (Leiomyoma)
  • Ovarian Tumors
  • Gallstones

Keywords

  • postoperative nausea and vomiting
  • transcutaneous electrical acupoint stimulation
  • high-risk patients with PONV
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women scheduled for laparoscopic surgery ;
  • Aged 18-65 years;
  • ASA Class I-III;
  • Apfel score ≥ 3 (female sex, non-smoker, history of PONV and/or motion sickness).

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of allergy to the drug or ;
  • Long- syndrome ;
  • Pregnancy, lactation, or menstruation ;
  • Current smoker;
  • Nausea/vomiting or use of antiemetics, opioids, or systemic within 24 h before surgery;
  • Requirement for post-operative sedation and mechanical ventilation ;
  • Severe renal or hepatic impairment ;
  • Psychiatric or neurological disorder ;
  • Vertebrobasilar insufficiency;
  • Vestibular disease;
  • Language or communication barrier ;
  • Skin lesion or infection at the acupoint stimulation site ;
  • Upper-limb nerve injury ;
  • Implanted cardiac pacemaker or defibrillator ;
  • Participation in another clinical trial within the past 4 weeks.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
780 participants (estimated)

Study arms

  • Experimental
    The TEAS group

    The TEAS group,Nei-guan (PC6) and He-gu (LI4) were stimulated by a transcutaneous acupoint electrical stimulation instrument approximately 30 minutes before anesthesia induction until the patient is discharged from the operating room.

    Device: transcutaneous electrical acupoint stimulation · Drug: triple antiemetic drugs

  • Sham comparator
    The control group

    The same protocol was applied for percutaneous acupoint electrical stimulation, initiated before anesthesia induction with the minimum perceptible current (MPC) and terminated after 1 minute. To ensure complete blinding, both groups were covered with opaque sheets over the percutaneous acupoint electrical stimulation device.

    Device: Sham transcutaneous electrical acupoint stimulation · Drug: triple antiemetic drugs

Interventions

  • Devicetranscutaneous electrical acupoint stimulation

    Using the Huatuo brand electronic acupuncture therapy device (Model: SDZ-Ⅲ, produced by Suzhou Medical Equipment Co., Ltd., China), bilateral upper limb acupoints P6+L14 were selected. Approximately 30 minutes before anesthesia induction, the electrodes were connected with the initial current set at 1 milliampere and frequency at 2/100 Hz. The current intensity was gradually increased until the patient felt pain or reached the discomfort threshold (ranging between 6 to 10 mA), and the stimulation was maintained until the patient was discharged from the PACU.

  • DeviceSham transcutaneous electrical acupoint stimulation

    The same protocol was applied for percutaneous acupoint electrical stimulation, initiated before anesthesia induction with the minimum perceptible current (MPC) and terminated after 1 minute.

  • Drugtriple antiemetic drugs

    Dexamethasone 5mg and palonosetron 0.25mg i.v. will be given after induction, and droperidol 1.25 mg i.v. will be given during the abdominal closure.

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Nausea,Retching and Vomiting within 24 hours after operation.

    The number of episodes of nausea, retching and vomiting within 24 hours after operation

    Time frame: 2 hours post-operation, 6 hours post-operation, 24 hours post-operation

Secondary outcomes

  1. Number of Participants Experiencing Postoperative Nausea in 48 h Postoperatively

    Nausea score: The severity of PON was measured using a visual analog scale (VAS), with 0 indicating no symptoms and 10 representing the most severe imaginable symptoms.

    Time frame: 2 hours post-operation, 6 hours post-operation, 24 hours post-operation, 48 hours post-operation

  2. Number of Participants Experiencing Postoperative Vomiting in 48 h Postoperatively

    including retching and vomiting

    Time frame: 2 hours post-operation, 6 hours post-operation, 24 hours post-operation, 48 hours post-operation

  3. Need of Postoperative Metoclopramide

    Need of Postoperative Metoclopramide

    Time frame: 2 hours post-operation, 6 hours post-operation, 24 hours post-operation, 48 hours post-operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.

Of 53 non-industry interventional studies with no phase under Leiomyoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 43. This study's planned 21 months is below that.

Counting every sponsor, half of 58 studies reached it within 31 months; a quarter within 15 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Mar 18, 2026
StartActual
Jan 16, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07480785
Collaborators
Jinhua Central Hospital, Huzhou Central Hospital, The First People's Hospital of Huzhou
Responsible party
Diansan Su (Chair of the Department of Anesthesiology, Zhejiang University) — Principal investigator
First posted
Mar 18, 2026
Start date
Jan 16, 2026
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Diansan Su, PhD
Contact
diansansu@yahoo.com
+8618616514088
Dongdong Tian
Contact
tddcomeon@163.com
+8615924165551

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion